"What" Series

What is the definition of a rare disease?

30 April 2024
2 min read

A rare disease, also known as an "orphan disease," refers to diseases with relatively low prevalence rates. The definition of rare diseases varies across different countries and regions, and these differences are typically based on prevalence rates, the number of patients, or other relevant factors.

·In the United States, the Orphan Drug Act enacted in 1983 provided a dual definition for rare diseases: diseases affecting fewer than 200,000 people in the U.S.; or diseases affecting more than 200,000 people, but for which the development and marketing costs of a drug are not expected to be recovered.

·In the European Union, a rare disease is defined as having a prevalence of less than 1 in 2,000 people.

·In China, the "China Rare Disease Definition Research Report 2021" proposed defining rare diseases as diseases with a neonatal incidence rate of less than 1 in 10,000, a prevalence rate of less than 1 in 10,000, or a total number of patients less than 140,000.

·In Japan, diseases affecting fewer than 50,000 people are defined as rare diseases.

Rare diseases often involve multiple systems and organs, and their clinical course is typically chronic, progressive, and debilitating, sometimes leading to disability or life-threatening conditions. Due to the small number of patients for each rare disease and the scarcity of information, the development of drugs for rare diseases is extremely challenging, and these drugs are sometimes referred to as "orphan drugs."

To address the challenges posed by rare diseases, some countries or regions have established relevant policies and regulations to promote the diagnosis, treatment, and research of rare diseases, while ensuring that patients can access necessary medical and social security support.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Testing Dosage of New T-cell Engager, ARB202, in Advanced Gastrointestinal Cancer Patients
Latest Hotspot
3 min read
Testing Dosage of New T-cell Engager, ARB202, in Advanced Gastrointestinal Cancer Patients
30 April 2024
Advanced gastrointestinal cancer patients continue to test dosages with the novel T-cell engager, CDH17 X CD3 cabotamig (ARB202).
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 29
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 29
29 April 2024
April 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Cidara Therapeutics Retakes Global Rights to CD388, Initiates $240M Funding Drive
Latest Hotspot
3 min read
Cidara Therapeutics Retakes Global Rights to CD388, Initiates $240M Funding Drive
28 April 2024
Cidara Therapeutics regains worldwide control for developing and marketing CD388, also launches a $240 million private funding initiative.
Read →
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
Hot Spotlight
3 min read
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
28 April 2024
On March 27th, Japan's Sosei Group Corporation announced that their board members and executives were reelected during the 34th Annual General Meeting and subsequent board meeting in Tokyo.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.